June 19, 2024
2 min watch
Save
VIDEO: Oral treatment shows promise in slowing diabetic retinopathy progression
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jay S. Pepose, MD, PhD, of Ocuphire Pharma, discusses an oral small-molecule Ref-1 inhibitor for nonproliferative diabetic retinopathy.
According to Pepose, the treatment slowed diabetic retinopathy progression in a phase 2 study and will soon enter a new clinical trial.
“If we can slow the progression of diabetic retinopathy that is associated with vision-threatening complications, this would be a huge paradigm shift for our patients,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Pepose reports being the chief medical advisor for Ocuphire Pharma.
Read more about